Bookbuilding IPO | ₹550 Cr | Listed at BSE, NSE | Mon, Jul 27, 2015 - Wed, Jul 29, 2015
Syngene International IPO is a book build issue of ₹550.00 crores. The issue is entirely an offer for sale of 2.20 crore shares of ₹550.00 crore.
Syngene International IPO bidding started from Jul 27, 2015 and ended on Jul 29, 2015. The shares got listed on BSE, NSE on Aug 11, 2015.
Syngene International IPO price band is set at ₹250 per share. The lot size for an application is 60. The minimum amount of investment required by an retail is ₹15,000 (60 shares) (based on upper price). The lot size investment for sNII is 14 lots (840 shares), amounting to ₹2,10,000, and for bNII, it is 67 lots (4,020 shares), amounting to ₹10,05,000.
Axis Bank Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Syngene International IPO RHP for detailed Information.
IPO Open
Mon, Jul 27, 2015
IPO Close
Wed, Jul 29, 2015
Issue Price
₹250 per share
Market Cap (Pre-IPO)
₹5,000.00 Cr
| IPO Date | 27 to 29 Jul, 2015 |
| Listed on | Tue, Aug 11, 2015 |
| Face Value | ₹10 per share |
| Price Band | ₹240 to ₹250 |
| Issue Price | ₹250 per share |
| Lot Size | 60 Shares |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,20,00,000 shares (agg. up to ₹550 Cr) |
| Offer for Sale | 2,20,00,000 shares of ₹10 (agg. up to ₹550 Cr) |
| Share Holding Pre Issue | 20,00,00,000 shares |
| Share Holding Post Issue | 20,00,00,000 shares |
| BSE Script Code / NSE Symbol | 539268 / SYNGENE |
| ISIN | INE398R01022 |
Syngene International IPO comprises a total issue size of 2,20,00,000 shares. The net offer to the public is 2,00,00,000 shares, after excluding 20,00,000 shares under a preferential allotment. Of the Net offer 1,00,00,000 (50.00%) are allocated to QIB, 30,00,000 (15.00%) allocated to NII 70,00,000 (35.00%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue | Max Allottees |
|---|---|---|---|---|
| QIB Shares Offered | 1,00,00,000 | 50.00% | 45.45% | NA |
| − Anchor Investor Shares Offered | 60,00,000 | 27.27% | NA | |
| − QIB (Ex. Anchor) Shares Offered | 40,00,000 | 18.18% | NA | |
| NII (HNI) Shares Offered | 30,00,000 | 15.00% | 13.64% | NA |
| Retail Shares Offered | 70,00,000 | 35.00% | 31.82% | 1,16,666 |
| Preferential Reservations | ||||
| Shareholders Shares Offered | 20,00,000 | 9.09% | NA | |
| Total Shares Offered | 2,20,00,000 | 100.00% | 100.00% | |
Investors can bid for a minimum of 60 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 60 | ₹15,000 |
| Retail (Max) | 13 | 780 | ₹1,95,000 |
| S-HNI (Min) | 14 | 840 | ₹2,10,000 |
| S-HNI (Max) | 66 | 3,960 | ₹9,90,000 |
| B-HNI (Min) | 67 | 4,020 | ₹10,05,000 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only shareholder | Up to Rs 2 Lakhs | Yes |
| Shareholder + RII/NII |
|
Yes for shareholder/RII |
Note: To be eligible for the Shareholder Quota, you must hold shares in one of the following companies:
Incorporated in 1993, Syngene International Ltd is a subsidiary of Biocon Limited ("Biocon"), a global biopharmaceutical enterprise focused on delivering affordable formulations and compounds.
Headquartered in Bengaluru, Syngene International is India-based contract research organisations ("CRO"), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities ("NMEs") across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. Their services in discovery and development cover multiple domains across small molecules, large molecules, antibody-drug conjugates ("ADC") and oligonucleotides.
Syngene offer customized models as per their clients requirements. These range from a full-time equivalent ("FTE") to a fee-for-service ("FFS") model, or a combination thereof. Till Dec 31, 2014, they serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014. Company's long term clients includes global healthcare organisations Bristol-Myers Squibb Co. ("BMS"), Abbott Laboratories (Singapore) Pte. Ltd. ("Abbott") and Baxter International Inc. ("Baxter").
| Period Ended |
|---|
| Amount in ₹ Crore |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | To Meet Working Capital Requirement | 28.40 |
| 2 | Public Issue Expenses | 4.00 |
The Syngene International IPO is subscribed 32.05 times on July 29, 2015 6:10:00 PM (Day 3). The public issue subscribed 4.78 times in the retail category, 51.47 times in the QIB category, and 90.24 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 51.47 | 40,00,000 | |
| NII | 90.24 | 30,00,000 | |
| Retail | 4.78 | 70,00,000 | |
| Others | 1.37 | 20,00,000 | |
| Total | 32.05 | 1,60,00,000 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Payment to Merchant Banker including underwriting and selling commissions, brokerages, payment to other intermediaries such as Legal Advisors, Registrars, etc and other out of pocket expenses | 3.40 |
| 2 | Printing and Stationery and postage expenses | 0.20 |
| 3 | Advertising and Marketing expenses | 0.20 |
| 4 | Other expenses | 0.20 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹250.00 | ₹250.00 |
| Open | ₹295.00 | ₹295.00 |
| Low | ₹295.00 | ₹295.00 |
| High | ₹318.20 | ₹318.50 |
| Last Trade | ₹310.40 | ₹310.55 |
Syngene International IPO is a main-board IPO of 2,20,00,000 equity shares of the face value of ₹10 aggregating up to ₹550 Crores. The issue is priced at ₹250 per share. The minimum order quantity is 60.
The IPO opens on Mon, Jul 27, 2015, and closes on Wed, Jul 29, 2015.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Syngene International IPO using UPI as a payment gateway. Zerodha customers can apply in Syngene International IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Syngene International IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Syngene International IPO opens on Mon, Jul 27, 2015 and closes on Wed, Jul 29, 2015.
Syngene International IPO lot size is 60, and the minimum amount required for application is ₹15,000.
You can apply in Syngene International IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Syngene International IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Syngene International IPO allotment status.
The Syngene International IPO listing date is on Tue, Aug 11, 2015.
